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Introduction
“There is no treatment”, this is the oldest known description 
of cancer, written on Egyptian papyrus around 3000BC, 
the era in which the Egyptians built the great pyramid 
of Giza, the oldest of the Seven Wonders of the ancient 
world. Through human history, the fight against cancer 
has never ceased. Enormous progress was achieved after 
the 19th century with use of the modern microscope in 
studying disease tissues (1). Over the past decades, survival 
rates for many cancers have increased impressively by the 
introduction of prevention, new drugs and multi-disciplinary 
treatments. In breast cancer, the five-year relative survival 
rate has soared from 63% in the early 1960s to 90% (2). 
Cancer no longer means “incurable disease”, and can be 
controlled in many patients. The World Health Organization 
(WHO) lists cancer as a chronic disease and in parallel 
with an aging population, the number of cancer patients is 
increasing. According to the latest world cancer statistics 
(GLOBOCAN 2012) (3), an estimated 14.1 million new 
cancer cases occurred in 2012, compared with 12.7 million 
in 2008; by 2025, there will be nearly 20 million new cancer 
cases per year. Cancers cost the European Union 124 billion 
Euros each year (4), about 10% of the total expenditure 
on healthcare. With limited resources, healthcare payers 
will in the future likely only pay for “performance” rather 
than for service. Treatments that prevent diseases, cure life-
threatening diseases, reduce the overall use of resources, 
and let patients stay as productive as possible: these are the 
approaches which the payers will support. 
Drug developers are facing enormous challenges, 
including the productivity crisis of their own. Between 
2002 and 2011, the pharmaceutical and biotech sector spent 
nearly 1.1 trillion dollars on research & development (R&D), 
and the United States Food and Drug Administration (FDA) 
approved 308 new molecular entities and biologics in the 
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10 years to 2011. That means the average cost per approved 
molecule ranged from 2.3 to 4.9 billion dollars (5). Only 
about two of every ten marketed drugs generate sufficient 
revues to cover their associated R&D cost (6). Compared to 
other clinical medicine, oncology has the highest attrition 
rate for late stage clinical trials, and overall success rate from 
first-in-man to approval is about 5% (7).
Cancer covers a complex and heterogeneous area of 
diseases and no two tumors, even of the same origin and 
histology, are identical. The previous perception of cancer as 
a distinct organ-specific disease is replaced by one of smaller 
entities responding to different biological pathways. Medical 
science is dynamic and making rapid progress, with massive 
investments in life sciences and availability of performing 
information technology (IT) tools. In 2001, to sequence an 
entire human genome cost 95 million US dollars. Today, it 
is done in a matter of hours at a cost of only 1,000 dollars. 
Pharmacogenomics helps us to understand how genetic 
variation affects individual response to therapy, with the twin 
aims of optimizing drug therapy and ensuring maximum 
efficacy with minimal side effects. Inexpensive and rapid 
gene sequencing may change the future medical practice. 
Yesterday’s challenge is today’s practice of a relatively 
large armamentarium of anti-cancer weapons; today’s 
challenge will be tomorrow’s practice of optimizing the use 
of treatments and translation of biology into therapeutic 
decisions. We have never had so many interactions between 
bench and bedside. Will those advanced techniques create 
the wonders of a new anti-cancer world?
Cancer drug developers need to build on our assets, and 
we propose to build on what could be depicted as “the seven 
wonders” for the future anticancer medicine world (Figure 1). The 
art will be learning how to articulate and combine them together.
Biomarkers
It is well recognized that patient’s genetic make-up and 
the tumor’s molecular profile can influence an individual’s 
response to specific therapies. A new era of personalized 
medicine has dawned in which therapy should be tailored 
to an individual’s disease and genetic profile. Effective 
integration of biomarkers into clinical drug development 
programs has been identified as a key prospect in the FDA’s 
Critical Path document (8). In novel drug development, the 
predictive value of validated biomarkers could inform crucial 
go/no go decisions around safety and efficacy. Biomarkers 
require the development of companion diagnostic tests 
able to select patients who are likely to respond to a given 
molecule, a “preselected” or “enriched” patient population. 
For example, panitumumab is a human monoclonal antibody 
to epidermal growth factor receptor (EGFR), approved for 
the treatment of patients with metastatic colorectal cancer, 
however the efficacy of panitumumab was restricted to 
patients with wild-type KRAS genes, while patients with 
mutated KRAS did not benefit. In addition, biomarkers are 
also used as a method to determine therapeutic interventions. 
It is challenging to develop an exact dose intervention that 
fits all patients due to the inter-individual variability. It may 
be possible to have a dose adjustment based on the genetic 
polymorphisms of drug-metabolizing enzymes or drug 
transporter proteins. Some drug labels have already been 
updated with biomarker information. For example, the 
azathioprine label added information related to thiopurine 
methyltransferase, and recommends that patients with 
thiopurine methyltransferase deficiency or lower activity are 
at increased risk for myelotoxicity. A list of valid genomic 
biomarkers identified in approved drug label could be found 
on the FDA website (9), which better informs healthcare 
professionals, and thereby helps to provide better patient 
care.
Effect ive  integrat ion of  b iomarkers  into drug 
development may facilitate and accelerate drug approval 
and promote personalized medicine. Nevertheless, the 
biomarker implementation into clinical practice or used 
Figure 1 Perspectives of the seven wonders for the future 
anticancer medicine world.
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in drug development must be pragmatic and carefully 
evaluated. As said by Artemas Ward, a famous American 
journalist: “It is not so much the things we don’t know that 
get us in trouble. It is the things we know that aren’t so”. 
Overpromising the utility of new biomarkers without 
adequate evidence will only hamper its usefulness in 
drug development and clinical therapy. The FDA issued 
a “Guidance for Industry: Pharmacogenomics Data 
Submissions” in 2005 (10), with the purpose of creating 
early interaction between regulatory and stakeholders 
without making a regulatory decision, allowing biomarker-
driven drug development to move forward effectively. 
Imaging
Imaging is another medical technique that benefits from the 
computer science revolution. Non-invasive imaging methods 
are widely used in cancer research for staging, diagnosis, 
response assessment, monitoring, etc. In drug development 
scenarios, tumor response is conventionally assessed by 
measuring the percentage of reduction in tumor size after 
chemotherapy. Vigorous debate has challenged the use of 
anatomic assessments alone, as it may take two or three 
months to detect any shrinkage. Some molecular imaging 
techniques provide an insight to tumor microenvironment 
in vivo and predict response or non-response at very early 
stage. For example, early metabolic response evaluation 
by 18F-fluorodeoxyglucose positron emission tomography 
(FDG-PET) al lows for an accurate prediction of 
histopathologic response during neoadjuvant chemotherapy 
in esophago-gastric cancer (11-13). The most important 
finding of these previous studies is the fact, that for patients 
not achieving a decrease of the FDG-uptake of ≥35% at 
2 weeks after the start of chemotherapy, the probability 
of responding after multiple doses is slim (FDG-PET 
negative predictive value is more than 95%). A reliable early 
identification of non-responding patients will be extremely 
valuable in guiding management and treatment, and to 
avoid that non-responsive patients are receiving unnecessary 
toxicity related to therapy. These advanced imaging 
technologies will allow for earlier selection of candidates for 
new drugs, and thereby reducing the large attrition rate in 
the pharmaceutical development process. Ultimately, patients 
will more rapidly have access to better treatments.
New imaging biomarkers are constantly being developed, 
and need to be qualified for full use in clinical research. 
Drug developers need to feel confident that a measured 
change in the imaging biomarker faithfully reflects the 
desired change in the underlying tumor pathology. 
Although imaging technologies such PET and magnetic 
resonance imaging (MRI) have existed for decades and are 
widely available, their full use in clinical research remains 
challenging. The quality and the comparability of images 
collected within international multi-center clinical trials are 
not optimal. Clinical research involving imaging can only 
be achieved within robust, quality assured, multi-site clinical 
trials supported by robust methodology and operational 
infrastructures allowing the processing, storage, and analysis 
of imaging data, which should be fully integrated with 
clinical and biological data. 
Quality assurance
Access to good quality biosamples or imaging data for 
translational research is fundamental to personalized cancer 
treatment; however, there are often major bottlenecks. 
For one thing, new skills are required to build on new 
platforms to integrate clinical, biological, and imaging 
data in the decision making process to control attrition 
rate of new drugs and/or decide on molecular sub-entities 
that will ultimately benefit new therapeutic strategies. In 
addition, currently there is no clear worldwide consensus 
on the criteria or level of quality assurance required either 
for different types of biomarker assay or for functional/
molecular imaging when those novel diagnostics are 
implemented in multi-center clinical trials. 
An infrastructure should implement common principles 
and guidelines for appropriate levels of quality assurance 
for biosample collection (e.g., centralized biobanking) 
with a sample tracking system, appropriate assay methods, 
and accredited laboratories to perform biomarker testing, 
supporting data management with biostatistics and 
bioinformatics experts for molecular data analysis and 
reporting. Some screening platforms are now emerging 
in clinical trials, as an example serves here the European 
Organisation for Research and Treatment of Cancer 
(EORTC) Screening Patients for Efficient Clinical Trial 
Access (SPECTA). The SPECTA colorectal cancer platform 
(SPECTAcolor) is the first prospective tumor tissue biobank 
and centralized biomarker analysis infrastructure for 
genetic profiling aiming at easy and targeted clinical trial 
access. Biosamples are collected with standard operational 
procedures, centrally tracked by the EORTC Headquarters 
using modern web-based IT tools. Systematic analysis and 
documentation enables us to establish reliable databases of 
patient molecular information, so as to enroll patients into 
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prospective biomarker-driven clinical trials.
Implementing functional imaging as companion 
diagnostics to assess response requires that an observed 
change of the imaging biomarker due to treatments must 
be greater than the intrinsic and extrinsic variability of the 
biomarker in the absence of treatment. High reproducibility 
of molecular and functional imaging techniques relies on 
good quality data and standardized procedure. In response 
to the challenges of imaging biomarker qualification, the 
Quantitative Imaging in Oncology: Connecting Cellular 
Processes to Therapy (QuIC-ConCePT) consortium 
was created and resourced by the Innovative Medicines 
Initiative (IMI), Europe’s largest public-private initiative. It 
aims to qualify three specific imaging biomarkers of tumor 
cell proliferation, apoptosis, and necrosis, to allow drug 
developers to demonstrate reliably the modulation of these 
pathologic processes in tumors of patients in future trials. 
The qualified imaging biomarkers will help drug developers 
in decision-making during phase I trials of investigational 
therapies, confident that the biomarkers are robust, 
consistent in multiple cancer centers, and reflective of the 
desired change in the underling tumor pathology. 
Clinical trial methodology
Drug development requires methodologically robust and 
practice-relevant clinical trials. Optimized phase II trial 
design with reasonable endpoints based on a strong biological 
rationale, will help to facilitate smaller, faster, and less expensive 
confirmatory phase III trials, or even give enough data to 
draw the necessary conclusion after phase II study and lead to 
successful drug approval. There are examples of blockbuster 
drugs that were approved by the FDA without phase III 
results, thanks to their vastly improved activity and limited 
toxicity relative to the standard of care for the disease under 
investigation. Imatinib (Glivec®, Gleevec®, Novartis), was 
developed rationally targeting bcr-abl protein. This protein is 
over-expressed in chronic myeloid leukemia (CML) due to a 
pathognomonic and driving fusion gene, leading to interrupted 
production of white blood cells in patients. The results of 
imatinib’s preliminary studies were dramatic: nearly every CML 
patients responded and only minimal side effects were reported. 
Before imatinib, prognosis was dismal and only 3 out of 10 
patients survived 5 years, today the 5-year survival rates are up to 
90%. The first phase I study began in June 1998, and the drug 
received the FDA approval in May 2001, only 10 weeks after the 
new drug application was submitted (14). Unfortunately, success 
stories like this are rare. We need more so-called “rational drug 
designs” in the future.
A study will have a large probability of failure if it is 
based on inaccurate estimations or unrealistic assumptions. 
Changes in design or analyses guided by the accumulated 
data at an interim point in the trial may make studies 
more efficient. For example, a conventional design to 
find optimal dose-response might use multiple fixed-size 
randomized groups to ensure that an optimal dose level is 
included, but including several groups with sub-optimal 
doses will decrease the study efficiency. An adaptive design 
can ascertain when further data collection for a particular 
group is not useful, and stop data collection, decreasing the 
cost and time while, when planned upfront and adequately, 
allows keeping the study’s integrity. Similarly, an adaptive 
design approach that can adjust the study sample size to 
avoid underpowered studies, e.g., the initial assumption of 
variance is too low or of treatment-effect size is too large.
Smart but robust clinical research methodology using 
adaptive design could shorten the trial duration, the size of 
the studied population and ultimately the trial costs. Drug 
developers should invest more money early on the knowledge 
of the molecular basis of a disease to reduce the risk of losing 
a lot of money and time further down the line. Modern 
clinical trial methodologies propose a wide range of adaptive 
designs that should be selected according to the research 
question e.g., phase II adaptive design, or “pick the winner”.
Combined treatment
Combination therapy whether it is combination of 
drugs, inhibition of multiple pathways or combination of 
modalities (e.g., combined chemo-radiotherapy) is of great 
importance in many disease settings, and in particular in 
oncology. Advances in biology and genomics have led to 
more development of targeted agents. However, modulation 
of one target may not be sufficient enough to achieve 
durable response. The use of multiple therapeutic agents is 
more likely to lead to therapeutic advances, as tumors may 
be driven by several pathways. New therapeutic approaches 
using combinations of drugs (multiple therapeutic targeted 
agents, or targeted agents + chemotherapy) can help to 
improve treatment response, minimize development 
of resistance, or minimize adverse events. Therefore, 
it is expected that co-development of two or more new 
combination drugs will increase. 
Combinations of two or more new therapeutic entities 
may be required to achieve measurable clinical benefit. 
However, parallel co-development in combination of two 
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new agents has its own challenges, as it will generally not 
provide sufficient information about safety and effectiveness 
of each of the individual new investigational drug. Ethical 
concerns and low efficacy when used alone may prevent 
conducting parallel-group comparison with each individual 
compound. On the other hand, for pharmaceutical 
companies, the combination of new compounds in the early 
development increases the risk of failure, since knowledge 
about drug interactions may be missing. Another obstacle 
for combining different drugs is the fact that the involvement 
of several companies within one trial creates challenges 
to data sharing, intellectual property and marketing 
concerns. The FDA has recently provided guidelines on 
the standard for licensing of new-new combination (15). 
According to these guidelines, the combination should 
be based on a strong biological rationale and promising 
preclinical data, proving that the combination is superior 
to existing treatments or to the individual agents alone. 
An early interaction with the FDA is suggested on the 
appropriateness of co-development before initiation of 
clinical development of a combination. 
Adaptive licensing (AL)
Traditional drug licensing is a binary decision, divided into 
two distinct phases: pre-licensing and post-licensing. During 
the pre-licensing phase, patients can only be exposed to a new 
drug/investigational product in clinical trials with informed 
consent procedures and specific eligibility criteria. Once 
approved, the drug is prescribed in the real world populations 
who need not to meet specific eligibility requirements. It is 
unrealistic to expect matching safety and effectiveness when 
a drug is used in a heterogeneous real-world population 
based on limited trial data. AL is based on stepwise learning, 
progressive management and reduction of uncertainty. It 
allows earlier access to patients with unmet medication 
needs (e.g., life-threatening disease), and patients, doctors, 
and regulators are all willing to take greater risks, including 
unknown efficacy and safety. Thus, the evaluation of AL is 
not binary but a continuum; pre- vs. post-licensing stages will 
be replaced by graded, more timely and cost-effective market 
entry, leading to greater market stability.
The idea of staggered approval was introduced in the 
European Medicines Agency’s (EMA) Road Map to 2015 
as a possible solution for earlier approval of drugs to reduce 
barriers to innovation, and provide timely access for patient 
with unmet medication needs. Similar proposals for adaptive 
approaches to drug licensing have emerged worldwide under 
various labels, including progressive licensing (Canada), 
accelerated approval (US), adaptive approval (Singapore) (16). 
These proposals vary in details, but all are based on continuous 
evaluation over time. Access to new drugs will combine data 
from clinical trials, observational data and effectiveness of 
drugs in real-world use and access control. 
AL may in some cases reduce time to full market 
approval. Although it should not be expected to reduce 
overall attrition rate, AL may reduce the overall cost of 
development by reducing expensive late stage failure 
and post-market withdrawals. Is it a new wonder for the 
anticancer medicine world? “Not a panacea, but necessarily 
a route for all drugs, one size doesn’t fit all”, are comments 
received from regulatory bodies (17). The AL pathway 
to market will likely vary on a case-by case basis. For a 
product used to treat a life-threatening disease, the quantity 
of data required for an initial authorization might be 
considerably less than that for a product used to treat a 
disease for which many treatments are available. The AL 
pathway for any drug should be based on the willingness of 
patients, doctors, payers, and regulators to accept a great 
level of uncertainty in term of safety and efficacy. Another 
important point is that all stakeholders will need to accept 
that initial approval is not just early but also conditional. 
Hence, a clear commitment is required from developers 
to continue conducting studies to collect data after initial 
licensing. “What is the appropriate regulatory action to 
take in the event that promised studies are not performed 
or expected data do not become available” is a critical issue 
as has been prominently highlighted by Avorn in 2007 (18). 
Taking no action would undermine the system, whereas 
restrictions of the license due only to lack of new data will, 
in the case of a potential lifesaving drug, be difficult to 
accept for patients and doctors. A wonder may become a 
mirage, a cruel illusion. Therefore, proper management and 
communication might be the best or only option to balance 
the regulators’ gatekeeper and enabler roles. Harmonization 
of the development plan across drug developers, regulators, 
and payers could be the way to ensure that sponsors 
continue to monitor their products and to collect data on 
the effectiveness of drugs in use. 
New forms of multi-stakeholder collaboration
Pharmaceutical companies are collaborating in co-
development of their individual products, offering a double-
team approach to fight cancer. It started in 2009, when 
AstraZeneca and Merck formed a partnership to evaluate 
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combination candidates and share all development costs. 
One of their success stories involves their capitalizing on 
the synergies of two different drug mechanisms, a MEK 
inhibitor (AZD6244) and a protein kinase B inhibitor 
(MK-22060) in non-small cell lung cancer, and speeded 
the development time (19). Similarly, Bristol-Myers 
Squibb and Roche are collaborating on a melanoma 
product (vemurafenib). In September 2012, ten leading 
biopharmaceutical companies formed a non-profit 
organization, TransCelerate BioPharma, with the mission to 
share research and solutions that will simplify and accelerate 
the delivery of exciting new medicines for patients. 
A new era of drug development will require strong 
collaboration between the industry and academics, as well 
as close communication with regulators and payers (20). 
Academic research organizations can provide scientific 
advice and clinical trial methodology, and also incorporate 
additional translational research projects. Commercial 
research organizations can support site monitoring and 
operational management. Industry can provide new agents 
as well as input for regulatory aspects. The responsibility 
split could maximize the strengths of each stakeholder. 
Conclusions
Thanks to high technology, drug developers’ future has never 
been so promising. We described in this review how clinical 
research and drug development may evolve in the coming 
years. The molecular determinants of cancer will be more 
known and better translated into new drugs and companion 
diagnostics. However, on average, pharmaceutical companies 
spend only 7% of their budget on target/mechanism selection 
and validation (5) (Figure 2A). We suggest adjusted investment 
percentages in future drug development (Figure 2B), with 
pharmaceutical companies increasing investment of its 
R&D budget in target selection and validation based on 
Figure 2 Current percentages of pharmaceutical companies’ expenditures on drug development and suggestions for future drug development. 
(A) Percentages of pharmaceutical companies’ expenditures on drug development, modified after PwC research: Pharma 2020- From vision to 
decision (5); (B) Suggestions for future drug development.
A
B
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genomic and genetic information; animal models should, by 
contrast, be used much less frequently because they provide 
an inaccurate means of predicting efficacy in humans. 
Optimized phase I/II studies based on a strong biological 
rationale will help to have more efficient and smaller phase 
III trials and lead to successful drug approval. AL could be 
another regulatory approach allowing patients with life-
threatening diseases to access novel treatments. Having good 
biological, imaging and clinical data for translational research 
is fundamental to personalized medicine, and eventually 
those achievements in bench side will bring high benefits to 
bedside when companion diagnostics are implemented in 
clinical research. Conducting modern clinical cancer trials 
demands optimized clinical methodology, good quality data, 
combined therapy, and multi-stakeholder collaboration, so as 
to accelerate patient access to new treatment and techniques.
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